Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures?

Immunotherapy

Volumn 5, Issue 2, 2013, Pages 105-107

  Barbuto, José Alexandre Marzagão ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cancer immunotherapy; cancer vaccines; dendritic cells; monocyte derived dendritic cells

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFECTION SENSITIVITY; LUNG INFECTION; MONOCYTE DERIVED DENDRITIC CELL; NEOPLASM; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VIRUS IMMUNITY; VIRUS INFECTION;

CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM; MONOCYTES; NEOPLASMS;

EID: 84874042221     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.153     Document Type: Review

References (14)

1. Dall'Oglio M, Srougi M, Barbuto JA. Complete response of metastatic renal cancer with dendritic cell vaccine. Int. Braz. J. Urol. 29(6), 517-519 (2003).
2. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1-22 (2012).
3. Palucka K, Banchereau J. Dendritic cells: A link between innate and adaptive immunity. J. Clin. Immunol. 19(1), 12-25 (1999).
4. Baleeiro RB, Anselmo LB, Soares FA et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol. Immunother. 57(9), 1335-1345 (2008).
5. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179(4), 1109-1118 (1994).
6. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166(6), 4254-4259 (2001).
7. Barbuto JA, Ensina LF, Neves AR et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. 53(12), 1111-1118 (2004).
8. Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients with cutaneous Tcell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102(7), 2338-2344 (2003).
9. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl Med. 4(127), 127ps8 (2012).
10. Robinson MK, Borghaei H, Adams GP, Weiner LM. Monoclonal Antibodies. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Vincent T, Devita J, Lawrence TS, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA (2011).
11. Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173(3), 647-658 (1991).
12. Carneiro-Sampaio M, Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. Infect. Immun. 75(4), 1545-1555 (2007).
13. Naik SH. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 86(5), 439-452 (2008).
14. Ramos RN, Chin LS, Dos Santos AP, Bergami-Santos PC, Laginha F, Barbuto JA. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J. Leuk. Biol. 92(3), 673-682 (2012).